PL2897604T3 - Kompozycje do ulepszenia funkcji mózgu - Google Patents

Kompozycje do ulepszenia funkcji mózgu

Info

Publication number: PL2897604T3
Authority: PL; Poland
Prior art keywords: compositions; improvement; brain function; brain; function
Prior art date: 2012-09-19

Application number

PL13773433T

Other languages

English (en)

Inventor

Stefan Pierzynowski

Original Assignee

Grespo Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-09-19

Filing date

2013-09-19

Publication date

2018-10-31

2013-09-19 Application filed by Grespo Ab filed Critical Grespo Ab

2018-10-31 Publication of PL2897604T3 publication Critical patent/PL2897604T3/pl

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/54—Mixtures of enzymes or proenzymes covered by more than a single one of groups A61K38/44 - A61K38/46 or A61K38/51 - A61K38/53
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01001—Alpha-amylase (3.2.1.1)

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Psychiatry (AREA)
Psychology (AREA)
Heart & Thoracic Surgery (AREA)
Vascular Medicine (AREA)
Ophthalmology & Optometry (AREA)
Nutrition Science (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Pain & Pain Management (AREA)
Hospice & Palliative Care (AREA)
Urology & Nephrology (AREA)
Cardiology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Enzymes And Modification Thereof (AREA)

PL13773433T 2012-09-19 2013-09-19 Kompozycje do ulepszenia funkcji mózgu PL2897604T3 (pl)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US201261703163P	2012-09-19	2012-09-19
SE1200567		2012-09-19
EP13773433.1A EP2897604B1 (en)	2012-09-19	2013-09-19	Compositions for improvement of brain function
PCT/SE2013/051098 WO2014046603A1 (en)	2012-09-19	2013-09-19	Compositions for improvement of brain function

Publications (1)

Publication Number	Publication Date
PL2897604T3 true PL2897604T3 (pl)	2018-10-31

Family

ID=49304297

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PL18178948.8T PL3398594T3 (pl)	2012-09-19	2013-09-19	Kompozycje do ulepszenia funkcji mózgu
PL13773433T PL2897604T3 (pl)	2012-09-19	2013-09-19	Kompozycje do ulepszenia funkcji mózgu

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
PL18178948.8T PL3398594T3 (pl)	2012-09-19	2013-09-19	Kompozycje do ulepszenia funkcji mózgu

Country Status (12)

Country	Link
US (4)	US9592211B2 (pl)
EP (2)	EP2897604B1 (pl)
JP (2)	JP6263540B2 (pl)
KR (1)	KR102198633B1 (pl)
CN (1)	CN104797248B (pl)
AU (1)	AU2013318686B2 (pl)
CA (1)	CA2884592C (pl)
DK (2)	DK3398594T3 (pl)
ES (2)	ES2993163T3 (pl)
FI (1)	FI3398594T3 (pl)
PL (2)	PL3398594T3 (pl)
WO (1)	WO2014046603A1 (pl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK3398594T3 (da) *	2012-09-19	2024-09-23	Grespo Ab	Sammensætninger til forbedring af hjernefunktion
WO2016083399A1 (en) *	2014-11-24	2016-06-02	Forschungsgesellschaft Für Arbeitsphysiologie Und Arbeitsschutz E. V.	Alpha-ketoglutarate in combination with glutamate dehydrogenase for treating hyperammonemia
WO2019038655A1 (en) *	2017-08-21	2019-02-28	The Regents Of The University Of California	COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES
US11802103B2 (en)	2018-09-25	2023-10-31	Ponce De Leon Health Designated Activity Company	Process of making calcium alpha-ketoglutarate
US20230310559A1 (en) *	2020-08-18	2023-10-05	St. Jude Children's Research Hospital, Inc.	Use of Amylase or Maltose to Treat or Prevent Neurodegeneration
WO2023200281A1 (ko) *	2022-04-15	2023-10-19	재단법인대구경북과학기술원	알츠하이머병 또는 경도 인지장애 진단을 위한 비응집성 용해조성물 및 이를 이용한 진단 방법
CN117530940A (zh) *	2023-10-11	2024-02-09	四川大学华西第二医院	α-酮戊二酸在制备促髓鞘修复、改善神经炎症的药物中的应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2711436B2 (ja)	1995-02-22	1998-02-10	マルホ株式会社	アレルギー治療剤及びアレルギー対応食品
DE69634248T2 (de)	1995-05-31	2006-01-12	Medzyme N.V.	Zusammensetzungen zur verbesserung der verdaulichkeit und ausnutzung von nähestoffen
US6372473B1 (en)	1997-05-28	2002-04-16	Human Genome Sciences, Inc.	Tissue plasminogen activator-like protease
ATE555780T1 (de)	1997-10-24	2012-05-15	John P Blass	Nahrungsergänzungsmittel für metabolische hirnleistungsstörungen
US20010046493A1 (en)	2000-02-24	2001-11-29	Alex Margolin	Lipase-containing composition and methods of use thereof
US20070053895A1 (en) *	2000-08-14	2007-03-08	Fallon Joan M	Method of treating and diagnosing parkinsons disease and related dysautonomic disorders
IL156766A0 (en)	2001-01-09	2004-02-08	Louis Johan Wagenaar	Procedure and composition of treatment and/or care of the eye
AR032392A1 (es)	2001-01-19	2003-11-05	Solvay Pharm Gmbh	Mezcla de enzimas, preparado farmaceutico y utilizacion de dicho preparado.
US6689810B2 (en)	2001-08-21	2004-02-10	Cellular Sciences, Inc.	Method for treating pulmonary disease states in mammals by altering indigenous in vivo levels of nitric oxide
US7122578B2 (en)	2001-09-11	2006-10-17	Alain Martin	Method and composition for treating mammalian diseases and injuries which cause pain, erythema, swelling, crusting, ischemia scarring and excess white blood cell infiltration
US8076373B2 (en)	2001-09-11	2011-12-13	North Cell Pharmacetical	Method for treating mammalian diseases and injuries caused by the over-expression of peroxynitrite
US7241456B2 (en)	2002-10-25	2007-07-10	Australian Importers Ltd.	Formulations for topical delivery of bioactive substances and methods for their use
JP4265997B2 (ja)	2004-07-14	2009-05-20	富士通マイクロエレクトロニクス株式会社	半導体装置及びその製造方法
PL369552A1 (pl) *	2004-08-12	2006-02-20	Sgp & Sons Ab	Preparat farmaceutyczny lub/i żywieniowy lub/i laboratoryjny wzmagający, wspomagający funkcjonowanie komórek nerwowych i układu nerwowego oraz zastosowanie preparatu farmaceutycznego lub/i żywieniowego w procesie ochrony funkcji układu nerwowego oraz zastosowanie preparatu do ochrony wzrostu stymulacji namnażania i zapobiegania apoptozie komórek nerwowych
WO2006044529A1 (en) *	2004-10-14	2006-04-27	Altus Pharmaceuticals Inc.	Compositions containing lipase; protease and amylase for treating pancreatic insufficiency
DK1824470T3 (da)	2004-12-17	2014-08-18	Cash Alan Brian	Fremgangsmåde til forlængelse af levetiden og forsinke starttidspunktet for alders-relateret sygdom
CN101371142A (zh)	2006-01-19	2009-02-18	安特瑞斯公司	诊断方法和治疗方法
PL226695B1 (pl)	2006-07-03	2017-08-31	Danuta Kruszewska	Środek do zastosowania w zapobieganiu i/lub hamowaniu kolonizacji Helicobacter pylori, zastosowanie soli kwasu alfa‑ketoglutarowego z metalami alkalicznymi i ziem alkalicznych do wytwarzania środka leczniczego oraz dodatku do żywności do zapobiegania i/lub hamowania kolonizacji Helicobacter pylori
ES2557160T3 (es) *	2006-10-23	2016-01-22	Nestec S.A.	Modulación del aroma y el sabor mediante biotransformación en productos lácteos
ES2560527T3 (es) *	2007-02-20	2016-02-19	Allergan Pharmaceuticals International Limited	Composiciones estables de enzimas digestivas
US11016104B2 (en)	2008-07-01	2021-05-25	Curemark, Llc	Methods and compositions for the treatment of symptoms of neurological and mental health disorders
US20100092447A1 (en) *	2008-10-03	2010-04-15	Fallon Joan M	Methods and compositions for the treatment of symptoms of prion diseases
CN102482713B (zh)	2009-05-11	2017-06-30	博格有限责任公司	利用表观代谢转变剂、多维细胞内分子或环境影响剂诊断肿瘤障碍的方法
CN101884631A (zh)	2009-05-12	2010-11-17	复旦大学	基于α酮戊二酸及其衍生物的抗肿瘤药物
CN102010890B (zh) *	2009-09-08	2013-05-22	北京迪迈医学诊断技术有限公司	线粒体天门冬氨酸氨基转移酶测定试剂盒
US20110064720A1 (en) *	2009-09-16	2011-03-17	Daniel Moses Amato	Dietary Supplement Compositions and Methods of Making and Using the Same
US9050306B2 (en)	2010-06-22	2015-06-09	Alan B. Cash	Activation of AMP-protein activated kinase by oxaloacetate compounds
RU2013112807A (ru)	2010-08-23	2014-09-27	Иссум Рисёрч Дивелопмент Компани Оф Зэ Хибру Юнивёрсити Оф Джерусалем Лтд.	Композиция для доставки активных агентов в желудок
WO2012078798A1 (en)	2010-12-07	2012-06-14	Bananalogix, Inc.	Methods of processing organic matter and compositions thereof
DK3398594T3 (da) *	2012-09-19	2024-09-23	Grespo Ab	Sammensætninger til forbedring af hjernefunktion

2013
- 2013-09-19 DK DK18178948.8T patent/DK3398594T3/da active
- 2013-09-19 PL PL18178948.8T patent/PL3398594T3/pl unknown
- 2013-09-19 ES ES18178948T patent/ES2993163T3/es active Active
- 2013-09-19 FI FIEP18178948.8T patent/FI3398594T3/sv active
- 2013-09-19 WO PCT/SE2013/051098 patent/WO2014046603A1/en not_active Ceased
- 2013-09-19 JP JP2015533015A patent/JP6263540B2/ja active Active
- 2013-09-19 AU AU2013318686A patent/AU2013318686B2/en active Active
- 2013-09-19 CA CA2884592A patent/CA2884592C/en active Active
- 2013-09-19 EP EP13773433.1A patent/EP2897604B1/en active Active
- 2013-09-19 ES ES13773433.1T patent/ES2681343T3/es active Active
- 2013-09-19 CN CN201380058821.4A patent/CN104797248B/zh active Active
- 2013-09-19 EP EP18178948.8A patent/EP3398594B1/en active Active
- 2013-09-19 US US14/428,841 patent/US9592211B2/en active Active
- 2013-09-19 PL PL13773433T patent/PL2897604T3/pl unknown
- 2013-09-19 DK DK13773433.1T patent/DK2897604T3/en active
- 2013-09-19 KR KR1020157009161A patent/KR102198633B1/ko active Active
2017
- 2017-03-02 US US15/447,974 patent/US20170333372A1/en not_active Abandoned
- 2017-10-25 JP JP2017205991A patent/JP2018048175A/ja active Pending
2021
- 2021-01-29 US US17/163,065 patent/US20210154160A1/en not_active Abandoned
2023
- 2023-10-25 US US18/494,126 patent/US20240065993A1/en not_active Abandoned

Also Published As

Publication number	Publication date
DK2897604T3 (en)	2018-08-06
JP2015529245A (ja)	2015-10-05
WO2014046603A1 (en)	2014-03-27
HK1207566A1 (en)	2016-02-05
CN104797248A (zh)	2015-07-22
ES2993163T3 (en)	2024-12-23
CA2884592A1 (en)	2014-03-27
US20150297544A1 (en)	2015-10-22
AU2013318686B2 (en)	2017-11-30
US20240065993A1 (en)	2024-02-29
EP3398594B1 (en)	2024-07-10
EP2897604B1 (en)	2018-07-04
US9592211B2 (en)	2017-03-14
CN104797248B (zh)	2017-10-31
US20170333372A1 (en)	2017-11-23
JP6263540B2 (ja)	2018-01-17
ES2681343T3 (es)	2018-09-12
US20210154160A1 (en)	2021-05-27
EP3398594A1 (en)	2018-11-07
AU2013318686A1 (en)	2015-04-02
KR20150058292A (ko)	2015-05-28
EP2897604A1 (en)	2015-07-29
CA2884592C (en)	2021-08-31
JP2018048175A (ja)	2018-03-29
DK3398594T3 (da)	2024-09-23
KR102198633B1 (ko)	2021-01-05
FI3398594T3 (en)	2024-09-23
PL3398594T3 (pl)	2024-11-04

Publication	Publication Date	Title
ZA201501847B (en)	2016-01-27	Formulations of enzalutamide
IL233649B (en)	2019-07-31	Preparations derived from chitosan
GB2511197B (en)	2017-05-03	Compositions
PL2897604T3 (pl)	2018-10-31	Kompozycje do ulepszenia funkcji mózgu
GB201501016D0 (en)	2015-03-04	Preparation of 18F-fluciclovine
GB201210800D0 (en)	2012-08-01	Compositions
GB201209244D0 (en)	2012-07-04	Compositions
GB201201287D0 (en)	2012-03-07	Compositions
ZA201502350B (en)	2017-08-30	Solid form of hihydro-pyrido-oxazine derivative
ZA201503102B (en)	2016-11-30	Finafloxacin suspension compositions
GB201220068D0 (en)	2012-12-19	Compositions
GB201318407D0 (en)	2013-12-04	Compositions
GB201219980D0 (en)	2012-12-19	Compositions
GB201219973D0 (en)	2012-12-19	Compositions
GB201219962D0 (en)	2012-12-19	Compositions
TWI561248B (en)	2016-12-11	Peracid-generating compositions
HUE036665T2 (hu)	2018-07-30	Dihidro-pirido-oxazin származék szilárd formái
EP2926813A4 (en)	2016-05-25	METFORMIN-Orlistat COMPOSITIONS
GB201223148D0 (en)	2013-02-06	Compositions
GB201222702D0 (en)	2013-01-30	Compositions
GB201218959D0 (en)	2012-12-05	Compositions
GB201209189D0 (en)	2012-07-04	Compositions
GB201209187D0 (en)	2012-07-04	Compositions
GB201204102D0 (en)	2012-04-18	Compositions
GB201204103D0 (en)	2012-04-18	Compositions